4th Quarter - Report

SOCIETY FOR MATERNAL-FETAL MEDICINE for SOCIETY FOR MATERNAL-FETAL MEDICINE

Firm
Client
Income
—
Expenses
$10,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Increases in funding in FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); SENATE; Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES

Health Issues HCR

maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1117 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.